The SAMS refers to a range of disorders from the rare rhabdomyolysis (1 in 10,000) to muscle pain with evidence of muscle damage or myopathy (1 in 2,000) to muscle symptoms without evidence of damage or myalgia (up to 1 in 10).55 The SLCO1B1 gene encoding the hepatic transporter OATP1B1 is the most validated gene underlying the risk for statin myopathy. Here, SLCO1B1 is linked to rhabdomyolysis.